BetterInvesting National Convention to Host Global Health Ventures Inc., CEO to Present GHLV Sublingual Drug Delivery System Sept. 17, 2011
Sep 16, 2011, 12:22 ET
VANCOUVER, Sept. 16, 2011 /PRNewswire/ -- Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with a focus on sublingual drug delivery, is pleased to announce that CEO Dr. Hassan Salari will introduce the company to BetterInvesting National Convention participants in a corporate presentation at 1:20 p.m. on Saturday, Sept. 17. Dr. Salari will discuss the company's Sublingual Drug Delivery System and the company's first product in clinical trials, X-Excite, along with the company's commercialization strategy and the management appointment of Dr. Lola Maksumova, M.D., Ph.D., as Senior Vice President and Chief Operating Officer.
Global Health Ventures has become a corporate sponsor of BetterInvesting, one of the largest non-profit retail investor organizations in the U.S. This sponsorship represents one facet of what will be Global Health Ventures' ongoing efforts to increase its exposure to the retail investor community.
Dr. Salari said: "We are pleased to present to the many investors at the BetterInvesting National Convention and are excited to have a platform for review by the investment community. The corporate presentation allows us to educate potential shareholders in more detail about our goals to commercialize our sublingual drug delivery system."
For a current corporate fact sheet, go to: http://premierstocks.tv/images/company_links/GHLVlogo.pdf
About Sublingual Technology
The Company's drug formulation is designed to enhance the delivery of the medical products faster to the body than current oral formulations. This under-the-tongue design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that the sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.
About Global Health Ventures
Global Health Ventures (OTCBB: GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has developed a new formulation for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with less drug breakdown in the liver or gastrointestinal system, a process that can reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the bloodstream faster than the oral route of delivery. The company has initiated the development of non-steroidal anti-inflammatory drugs (NSAIDs). Several NSAIDs have been demonstrated to carry gastrointestinal side effects that prevent patients from using them effectively. The Company also has the drug "Relax-B" under development in Canada for anxiety. The next drug will be an anti-migraine treatment. The Company plans to use the same technology to deliver a vast number of other FDA-approved drugs that require faster delivery or reduced hepatic and gastrointestinal side effects. These include anti-stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Empowering investors since 1951, BetterInvesting is the brand identity of the National Association of Investors Corporation, a national, nonprofit association with members consisting of individual investors and investment clubs. With headquarters in Madison Heights, Mich., BetterInvesting is considered the voice of the individual investor, as well as the pioneer of the modern investment club movement. BetterInvesting is dedicated to providing a sound program of investment education and information to help its members become successful long-term, lifetime investors. For more information about BetterInvesting, visit its website at www.betterinvesting.org or call toll free (877) 275-6242. For additional BetterInvesting data and news releases, visit the Media Center at www.betterinvesting.org/mediacenter.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
Share this article